Industrial Purity Specifications for 2',3',5'-Triacetyl-5-Azacytidine
- High Purity Standards: Industrial grade material typically exceeds 98% purity via HPLC analysis, critical for downstream API synthesis.
- Optimized Synthesis: Established manufacturing process utilizes trimethylsilylation and glycosylation for maximum yield.
- Global Supply Chain: Reliable bulk procurement ensures consistent quality for epigenetic research and pharmaceutical development.
In the landscape of nucleoside analogues, 2',3',5'-Triacetyl-5-Azacytidine serves as a pivotal intermediate for the production of azacitidine, a potent DNA methyltransferase (DNMT) inhibitor. This compound is essential for developing treatments targeting myelodysplastic syndromes (MDS) and various malignancies. For pharmaceutical manufacturers and research institutions, securing material with verified industrial purity is not merely a regulatory requirement but a fundamental necessity for ensuring consistent reaction yields in subsequent deprotection steps. As a premier global manufacturer, NINGBO INNO PHARMCHEM CO.,LTD. adheres to strict quality control protocols to deliver intermediates that meet the rigorous demands of modern drug discovery.
Chemical Identity and Structural Characteristics
The chemical structure of this triacetylated nucleoside is defined by the protection of the ribose hydroxyl groups, which enhances lipophilicity and stability compared to the parent nucleoside. In chemical registries, the compound is frequently identified by systematic names such as 1,3,5-Triazin-2(1H)-one,4-amino-1-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl). Understanding the precise stereochemistry is vital, as the beta-configuration at the anomeric center is required for biological activity. When evaluating technical data sheets, buyers often cross-reference the structure against the identifier 2',3',5'-Triacetyl-azacytidine to ensure the correct isomer is procured. The acetyl groups protect the sugar moiety during transport and storage, preventing premature hydrolysis which could compromise the COA specifications upon arrival.
Optimized Synthesis Route and Manufacturing Process
The commercial viability of this intermediate depends heavily on an efficient synthesis route that balances cost with yield. The standard manufacturing process involves the condensation of trimethylsilylated-5-azacytosine with 1,2,3,5-tetra-O-acetyl-β-D-ribofuranose. This glycosylation reaction is typically catalyzed by trimethylsilyl trifluoromethanesulfonate (TMSOTf) in anhydrous acetonitrile.
Key stages in the production cycle include:
- Silylation: 5-azacytosine is treated with hexamethyldisilazane (HMDS) and ammonium sulfate under reflux to generate the trimethylsilylated derivative.
- Condensation: The silylated base is reacted with the peracetylated sugar at controlled temperatures (0°C to room temperature) to dictate stereoselectivity.
- Purification: Crude product is subjected to rigorous recrystallization to remove unreacted starting materials and side products, ensuring the final industrial purity exceeds 98%.
Optimizing the reflux times and vacuum distillation steps during the removal of excess HMDS is critical for maximizing overall yield. Manufacturers must monitor the reaction closely to prevent degradation of the triazine ring, which is sensitive to harsh acidic or basic conditions during workup.
Quality Control and Analytical Specifications
For bulk procurement, the Certificate of Analysis (COA) is the primary document verifying quality. A comprehensive COA should detail the assay method, typically High-Performance Liquid Chromatography (HPLC), along with limits for related substances and residual solvents. The table below outlines typical acceptance criteria for pharmaceutical-grade intermediates.
| Parameter | Specification | Test Method |
|---|---|---|
| Appearance | White to Off-White Crystalline Solid | Visual |
| Assay (HPLC) | ≥ 98.0% | Area Normalization |
| Single Impurity | ≤ 0.5% | HPLC |
| Total Impurities | ≤ 1.0% | HPLC |
| Loss on Drying | ≤ 0.5% | Karl Fischer / LOD |
| Residual Solvents | Compliant with ICH Q3C | GC |
Maintaining these specifications requires robust quality assurance systems. Deviations in purity can significantly impact the downstream deacetylation step used to generate active azacitidine. Therefore, verifying the bulk price against the provided purity metrics is essential for cost-effective production planning.
Storage Stability and Handling Protocols
Although the acetyl groups provide enhanced stability compared to the free nucleoside, 2',3',5'-triacetyl-5-azacytosine derivatives are still susceptible to hydrolysis in the presence of moisture. To maintain integrity, the material should be stored in a dark environment at 2-8°C, filled with inert gas such as nitrogen or argon. Exposure to ambient humidity can lead to the cleavage of ester bonds, resulting in the formation of diacetyl or monoacetyl impurities that are difficult to separate later.
Solubility data indicates the compound is soluble in polar aprotic solvents like dimethyl sulfoxide (DMSO) and dimethylformamide (DMF) at concentrations up to 30 mg/mL. This property is leveraged during analytical testing and subsequent coupling reactions. Proper handling ensures that the physical characteristics, such as the crystalline solid state and melting point range (approx. 497°C with decomposition), remain consistent with the batch records.
Procurement and Commercial Availability
Sourcing this intermediate from a reliable supplier mitigates the risk of supply chain disruptions in API manufacturing. When procuring 4-amino-1-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl) based intermediates, buyers should prioritize vendors who offer transparent documentation and scalable production capacities. The market demand for epigenetic modulators continues to rise, driving the need for consistent availability of high-quality nucleoside building blocks.
NINGBO INNO PHARMCHEM CO.,LTD. supports global pharmaceutical partners with customized synthesis capabilities and large-scale production options. By focusing on technical excellence and regulatory compliance, we ensure that every batch meets the stringent requirements necessary for clinical and commercial applications. Whether for synthesis route development or direct API production, securing a stable supply of verified intermediates is the cornerstone of successful drug development.
Conclusion
The production of 2',3',5'-Triacetyl-5-Azacytidine requires precise control over reaction conditions and purification methods to achieve the necessary industrial purity. From the initial silylation to the final recrystallization, every step impacts the quality of the final product. By partnering with established manufacturers who prioritize quality control and offer comprehensive COA documentation, pharmaceutical companies can ensure the efficacy and safety of their downstream products. For reliable bulk supply and technical support, industry leaders trust NINGBO INNO PHARMCHEM CO.,LTD. to deliver exceptional chemical solutions.